Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 1 · 25%High 1 · 25%

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).

1 finding from 1 review